C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/113 (2010.01) A61K 31/7088 (2006.01) A61K 31/712 (2006.01) A61K 47/48 (2006.01) A61P 11/06 (2006.01) A61P 21/00 (2006.01) A61P 35/00 (2006.01) C07H 21/00 (2006.01)
Patent
CA 2728762
The present invention relates to oligomer compounds (oligomers), which target Hsp27 mRNA in a cell, leading to reduced expression of Hsp27. Reduction of Hsp27 expression is beneficial for the treatment of certain medical disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of Hsp27 using said oligomers, including methods of treatment.
La présente invention porte sur des composés oligomères (des oligomères) qui ciblent l'ARNm du Hsp27 dans une cellule, conduisant à une expression réduite du Hsp27. La réduction de l'expression du Hsp27 est avantageuse pour le traitement de certains troubles médicaux tels que le cancer. L'invention concerne des compositions thérapeutiques comprenant des oligomères, et des procédés de modulation de l'expression du Hsp27 à l'aide de ces oligomères, y compris des méthodes de traitement.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Enzon Pharmaceuticals Inc.
Santaris Pharma A/s
LandOfFree
Rna antagonists targeting hsp27 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rna antagonists targeting hsp27, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rna antagonists targeting hsp27 will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1348859